Leading-edge CRISPR biotech chooses FSHD as its first disease target
We introduce this important piece of research making use of a comment from Prof. Massimiliano Filosto, vice president of the UILDM medical-scientific commission and clinical director of NeMO Brescia and leader of the AIM-FSHD group that the FSHD patients of UILDM’s Group have consulted to learn more.